Mbah, Nneka E.
Myers, Amy L.
Sajjakulnukit, Peter https://orcid.org/0000-0002-8556-7481
Chung, Chan https://orcid.org/0000-0003-0510-8996
Thompson, Joyce K.
Hong, Hanna S. https://orcid.org/0000-0003-1202-2808
Giza, Heather
Dang, Derek
Nwosu, Zeribe C. https://orcid.org/0000-0003-1641-2045
Shan, Mengrou
Sweha, Stefan R.
Maydan, Daniella D.
Chen, Brandon https://orcid.org/0000-0002-6319-2228
Zhang, Li
Magnuson, Brian
Zhu, Zirui https://orcid.org/0000-0003-4008-6518
Radyk, Megan
Lavoie, Brooke
Yadav, Viveka Nand
Koo, Imhoi https://orcid.org/0000-0002-5816-0627
Patterson, Andrew D. https://orcid.org/0000-0003-2073-0070
Wahl, Daniel R. https://orcid.org/0000-0001-9894-5085
Franchi, Luigi
Agnihotri, Sameer
Koschmann, Carl J.
Venneti, Sriram
Lyssiotis, Costas A. https://orcid.org/0000-0001-9309-6141
Funding for this research was provided by:
Alex's Lemonade Stand Foundation for Childhood Cancer
Alex's Lemonade Stand Foundation for Childhood Cancer
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS124607, R01NS110572, R01NS110572, 1R01NS127799)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
U.S. Department of Defense (CA201129P1)
Alex's Lemonade Stand Foundation for Childhood Cancer
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA261926)
Article History
Received: 1 March 2022
Accepted: 27 September 2024
First Online: 17 October 2024
Competing interests
: In the past three years, C.A.L. has consulted for Astellas Pharmaceuticals, Odyssey Therapeutics, Third Rock Ventures, and T-Knife Therapeutics, and is an inventor on patents pertaining to K-Ras regulated metabolic pathways, redox control pathways in pancreatic cancer, and targeting the GOT1-ME1 pathway as a therapeutic approach (US Patent No: 2015126580-A1, 05/07/2015; US Patent No: 20190136238, 05/09/2019; International Patent No: WO2013177426-A2, 04/23/2015). All other authors declare no competing interests.